Thanks for this article. I have a Motley account but never saw this. This evaluation is fairly short but covers all of the main parts of IMMU and this technology and history, and the future.
I know a lot of people in here think selling IMMU at some time soon after the 132 approval is the route to go, but, this small accounting of future opportunities IDAHO just posted, to me, looks very promising. Of course, no one can predict the future, and there's all sorts of things that could go wrong. And selling IMMU at the right time and right price will produce the icing on the cake and a substantial bump in price. From what we've seen, heard and read over the last several months, but the recent developments being a highlight, if IMMU can get 132 going and expanding into other areas of oncology, I see IMMU being a $100 stock in the next 2 to 4 years maybe more. Would it be better to keep IMMU as it's own producer and investigator and look to a level of value we all dream about getting into on the ground floor. We're no longer in the basement, maybe up to the 1st or 2nd floor. But, the penthouse at the top is looking more appealing all the time. Makes ya think.